HighVista Strategies has significantly reduced its stake in Viridian Therapeutics (VRDN), selling 238,243 shares valued at approximately $7.08 million, according to a May 15, 2026 SEC filing. This divestment comes as the stock has seen a notable 35% increase over the past year, outperforming the S&P 500, which gained about 25% in the same period. However, the quarterly position value declined by $8.97 million, indicating some volatility in investor sentiment.
Viridian Therapeutics, a clinical-stage biotech firm focused on monoclonal antibody therapies for thyroid eye disease, is preparing for a pivotal FDA decision regarding its lead therapy, veligrotug, due on June 30. While the recent Phase 3 trial data was positive, it fell short of expectations, leading to a sharp decline in share price. Still, the company remains optimistic about its product pipeline, including the promising subcutaneous candidate elegrobart.
For investors, HighVista’s sale may signal caution ahead of the FDA decision, but Viridian’s strong pipeline and potential market differentiation could offer significant upside if execution aligns with expectations.
Source: fool.com